Desheng Weng

State Key Laboratory Of Oncology In South China, Guangdong Key Laboratory Of Nasopharyngeal Carcinoma Diagnosis And Therapy
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial.

Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 08, 2026

Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.

Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 30, 2026

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

Journal: Breast cancer research and treatment

Published: January 05, 2026

HNRNPD Induces Radioresistance in Nasopharyngeal Carcinoma by Sequestering GRAMD4 mRNA in Stress Granules.

HNRNPD Induces Radioresistance in Nasopharyngeal Carcinoma by Sequestering GRAMD4 mRNA in Stress Granules.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 23, 2025

The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers.

The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 20, 2025

Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma.

Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma.

Journal: International journal of biological sciences

Published: January 13, 2025

Transformable Tumor Microenvironment-Responsive Oxygen Vacancy-Rich MnO2@Hydroxyapatite Nanospheres for Highly Efficient Cancer Sonodynamic Immunotherapy.

Transformable Tumor Microenvironment-Responsive Oxygen Vacancy-Rich MnO2@Hydroxyapatite Nanospheres for Highly Efficient Cancer Sonodynamic Immunotherapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 02, 2024

Personalized Prediction of prognosis in ebv-associated lymphoepithelioma-like carcinoma: insights from a Chinese cohort study.

Personalized Prediction of prognosis in ebv-associated lymphoepithelioma-like carcinoma: insights from a Chinese cohort study.

Journal: BMC cancer

Published: September 07, 2024

Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma.

Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma.

Journal: Cell death & disease

Published: August 13, 2024

EBV-associated epithelial cancers cells promote vasculogenic mimicry formation via a secretory cross-talk with the immune microenvironment.

EBV-associated epithelial cancers cells promote vasculogenic mimicry formation via a secretory cross-talk with the immune microenvironment.

Journal: Theranostics

Published: June 27, 2024

EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.

EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.

Journal: Journal for immunotherapy of cancer

Published: May 21, 2024

Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population.

Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population.

Journal: BMC cancer

Published: April 09, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026